ePrescribing: Reducing Costs through In-Class Therapeutic Interchange

Summary

Introduction Spending on pharmaceuticals in the US reached $373.9 billion in 2014. Therapeutic interchange offers potential medication cost savings by replacing a prescribed drug for an equally efficacious therapeutic alternative.

Methods Hard-stop therapeutic interchange recommendation alerts were developed for four medication classes (HMG-CoA reductase inhibitors, serotonin receptor agonists, intranasal steroid sprays, and proton-pump inhibitors) in an electronic prescription-writing tool for outpatient prescriptions. Using prescription data from January 2012 to June 2015, the Compliance Ratio (CR) was calculated by dividing the number of prescriptions with recommended therapeutic interchange medications by the number of prescriptions with non-recommended medications to measure effectiveness. To explore potential cost savings, prescription data and medication costs were analyzed for the 45,000 Vanderbilt Employee Health Plan members.

Results for all medication classes, significant improvements were demonstrated – the CR improved (proton-pump inhibitors 2.8 to 5.32, nasal steroids 2.44 to 8.16, statins 2.06 to 5.51, and serotonin receptor agonists 0.8 to 1.52). Quarterly savings through the four therapeutic interchange interventions combined exceeded $200,000 with an estimated annual savings for the health plan of $800,000, or more than $17 per member.

Conclusion A therapeutic interchange clinical decision support tool at the point of prescribing resulted in increased compliance with recommendations for outpatient prescriptions while producing substantial cost savings to the Vanderbilt Employee Health Plan – $17.77 per member per year.

Therapeutic interchange rules require rational targeting, appropriate governance, and vigilant content updates.

Citation: Stenner SP, Chakravarthy R, Johnson KB, Miller WL, Olson J, Wickizer M, Johnson NN, Ohmer R, Uskavitch DR, Bernard GR, Neal EB, Lehmann CU. eprescribing: reducing costs through in-class therapeutic interchange.

Keywords

Therapeutic interchange - electronic prescribing - cost savings - electronic health record

 

Conflict of Interest

The authors work for Vanderbilt University or Navitus. They have no other conflicts of interest.

• References

• 1 Centers for Medicare and Medicaid Services. National Health Expenditures 2012 Highlights. Available online at https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/downloads/highlights.pdf Last accessed May 10, 2015.
• 2 Centers for Medicare and Medicaid Services. National Health Expenditures 2013 Highlights. Available online at http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/Downloads/highlights.pdf Last accessed May 10, 2015.
• 3 IMS Institute for Healthcare Informatics. Medicines Use and Spending Shifts: A Review of the Use of Medicines in the U.S. in 2014. Available online at http://www.redaccionmedica.com/contenido/images/IIHI_Use_of_Medicines_Report_2015.pdf Last accessed May 14, 2015.
• 4 Lorenzetti L. The U.S. Has the Highest Drug Prices in the World. And Hating Martin Shkreli Won’t Be Enough to Change It. Fortune 2015; 172 (06) 17-18 PubMed PMID: 26875209.
• 5 Daemmrich A, Mohanty A. Healthcare reform in the United States and China: pharmaceutical market implications. J Pharm Policy Pract 2014; 07 (01) 9 doi: 10.1186/2052–3211–7–9. eCollection 2014. PubMed PMID: 25097759; PubMed Central PMCID: PMC4117976.
• 6 Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353 (05) 487-497 Review. PubMed PMID: 16079372.
• 7 Schoen C, Osborn R, Squires D, Doty MM. Access, affordability, and insurance complexity are often worse in the United States compared to ten other countries. Health Aff (Millwood) 2013; 32 (12) 2205-2215 doi: 10.1377/hlthaff.2013.0879. Epub 2013 Nov 13. PubMed PMID: 24226092.
• 8 Eisenberg JM. Physician utilization: the state of research about physicians’ practice patterns. Med Care 2002; 40 (11) 1016-1035 PubMed PMID: 12409848.
• 9 Pham HH, Alexander GC, O’Malley AS. Physician consideration of patients’ out-of-pocket costs in making common clinical decisions. Arch Intern Med 2007; 167 (07) 663-668 PubMed PMID: 17420424.
• 10 Gray T, Bertch K, Galt K, Gonyeau M, Karpiuk E, Oyen L, Sudekum MJ, Vermeulen LC. American College of Clinical Pharmacy. Guidelines for therapeutic interchange-2004. Pharmacotherapy 2005; 25 (11) 1666-1680 PubMed PMID: 16232030.
• 11 U.S. Food and Drug Administration. Generic Drugs: Questions and Answers. Available online at http://www.fda.gov/Drugs/ResourcesForYou/Consumers/QuestionsAnswers/ucm100100.htm Last accessed Jun 19, 2015.
• 12 Holmes Jr DR, Becker JA, Granger CB, Limacher MC, Page 2nd RL, Sila C. ACCF/AHA 2011 health policy statement on therapeutic interchange and substitution: a report of the American College of Cardiology Foundation Clinical Quality Committee. Circulation 2011; 124 (11) 1290-1310 doi: 10.1161/CIR.0b013e31822d97d5. Epub 2011 Aug 15. Review. Erratum in: Circulation 2011; 124(13): e364. PubMed PMID: 21844072.
• 13 Lau BD, Pinto BL, Thiemann DR, Lehmann CU. Budget impact analysis of conversion from intravenous to oral medication when clinically eligible for oral intake. Clin Ther 2011; 33 (11) 1792-1796 doi: 10.1016/j.clinthera.2011.09.030. PubMed PMID: 22001356.
• 14 Agwu AL, Lee CK, Jain SK, Murray KL, Topolski J, Miller RE, Townsend T, Lehmann CU. A World Wide Web-based antimicrobial stewardship program improves efficiency, communication, and user satisfaction and reduces cost in a tertiary care pediatric medical center. Clin Infect Dis 2008; 47 (06) 747-753 doi: 10.1086/591133. PubMed PMID: 18680419.
• 15 Venugopal V, Lehmann CU, Diener-West M, Agwu AL. Longitudinal evaluation of a World Wide Webbased antimicrobial stewardship program: assessing factors associated with approval patterns and trends over time. Am J Infect Control 2014; 42 (02) 100-105 doi: 10.1016/j.ajic.2013.09.018. PubMed PMID: 24485366.
• 16 Sick AC, Lehmann CU, Tamma PD, Lee CK, Agwu AL. Sustained savings from a longitudinal cost analysis of an internet-based preapproval antimicrobial stewardship program. Infect Control Hosp Epidemiol 2013; 34 (06) 573-580 doi: 10.1086/670625. Epub 2013 Apr 18. PubMed PMID: 23651887.
• 17 Thomas L, Culley EJ, Gladowski P, Goff V, Fong J, Marche SM. Longitudinal analysis of the costs associated with inpatient initiation and subsequent outpatient continuation of proton pump inhibitor therapy for stress ulcer prophylaxis in a large managed care organization. J Manag Care Pharm 2010; 16 (02) 122-129 PubMed PMID: 20178397.
• 18 Lucio SD, Stevenson JG, Hoffman JM. Biosimilars: Implications for health-system pharmacists. Am J Health Syst Pharm 2013; 70 (22) 2004-2017 doi: 10.2146/ajhp130119. PubMed PMID: 24173009; PubMed Central PMCID: PMC4203383.
• 19 Schachtner JM, Guharoy R, Medicis JJ, Newman N, Speizer R. Prevalence and cost savings of therapeutic interchange among U.S. hospitals. Am J Health Syst Pharm 2002; 59 (06) 529-533 PubMed PMID: 11908245.
• 20 Pedersen CA, Schneider PJ, Scheckelhoff DJ. ASHP national survey of pharmacy practice in hospital settings: Prescribing and transcribing-2013. Am J Health Syst Pharm 2014; 71 (11) 924-942 doi: 10.2146/ajhp140032. PubMed PMID: 24830997.
• 21 Helmons PJ, Coates CR, Kosterink JG, Daniels CE. Decision support at the point of prescribing to increase formulary adherence. Am J Health Syst Pharm 2015; 72 (05) 408-413 doi: 10.2146/ajhp140388. PubMed PMID: 25694416.
• 22 Carroll NV. How effectively do managed care organizations influence prescribing and dispensing decisions?. Am J Manag Care 2002; 08 (12) 1041-1054 Review. PubMed PMID: 12500881.
• 23 Stenner SP, Chen Q, Johnson KB. Impact of generic substitution decision support on electronic prescribing behavior. J Am Med Inform Assoc 2010; 17 (06) 681-688 doi: 10.1136/jamia.2009.002568. PubMed PMID: 20962131; PubMed Central PMCID: PMC3DS.
• 24 Loftus P. Doctors net billions from drug firms. The Wall Street Journal. Sept 30, 2014 Available online at http://www.wsj.com/articles/u-s-agency-reveals-drug-makers-payments-to-doctors-1412100323 Last accessed May 14, 2015.
• 25 Schumock GT, Nutescu EA, Walton SM, Arondekar BV, Lewis RK. Survey of hospital policies regarding low-molecular-weight heparins. Am J Health Syst Pharm 2002; 59 (06) 534-538 PubMed PMID: 11908246.
• 26 Poole TA. Survey of pharmacists’ and physicians’ perceptions of therapeutic interchange. Adv Ther 2005; 22 (01) 1-9 PubMed PMID: 15943216.
• 27 Miller RA, Waitman LR, Chen S, Rosenbloom ST. The anatomy of decision support during inpatient care provider order entry (CPOE): empirical observations from a decade of CPOE experience at Vanderbilt. J Biomed Inform 2005; 38 (06) 469-485 PubMed PMID: 16290243; PubMed Central PMCID: PMC1518541.
• 28 Pruszydlo MG, Walk-Fritz SU, Hoppe-Tichy T, Kaltschmidt J, Haefeli WE. Development and evaluation of a computerised clinical decision support system for switching drugs at the interface between primary and tertiary care. BMC Med Inform Decis Mak 2012; 12: 137 doi: 10.1186/1472–6947–12–137. PubMed PMID: 23185973; PubMed Central PMCID: PMC3518241.
• 29 Lee YY, Hsiao P, Lin YM, Yen YH, Chen HY. Successful implementation of a P&T-approved therapeutic interchange program of angiotensin II receptor blockers in a medical center in Taiwan. Value Health 2012; 15 (Suppl. 01) S111-S115 doi: 10.1016/j.jval.2011.11.001. PubMed PMID: 22265056.